Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Explore Regeneron Pharmaceuticals analyst ratings and price targets (NASDAQ:REGN) on Benzinga. Stay updated on expert opinions and forecasts for REGN stock.

Investing.com - UBS raised its price target on Regeneron Pharmaceuticals (NASDAQ: REGN) to $584.00 from $560.00 while maintaining a Neutral rating on the stock.

Despite Regeneron Pharmaceuticals’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, ...

Leerink Partners also adjusted Regeneron's stock, reducing the price target from $880 to $762 and maintaining a Market Perform rating. This adjustment was influenced by pressures on the Eylea ...

Analyst Ratings Published 05/30/2025, 01:24 PM 0 RBC Capital cuts Regeneron stock rating, slashes target to $662 REGN 2.37% ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on ...

The Significance of Analyst Ratings Explained Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems.